Metastatic Neuroendocrine Carcinoma

3 clinical trials · Condition

Record	Firm	Date
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (NCT04514497)	National Cancer Institute (NCI)	2021-10-20
Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors (NCT04079712)	National Cancer Institute (NCI)	2020-08-06
Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer (NCT03728361)	Dwight Owen	2018-12-31

Every clearance here is in the API, with alerts when new ones post.